We integrate scientific rigor with strategic foresight to design evidence-driven development programs that withstand regulatory scrutiny and deliver commercial value. From IND/BLA submissions to HEOR frameworks and market access strategy, we ensure every clinical decision aligns with approval goals and patient impact.
With almost two decades leading global submissions and managing $85M+ portfolios, we deliver senior-level expertise with boutique agility. We’ve guided successful programs across CNS therapeutics, biologics, and regenerative medicine connecting discovery to regulatory approval to market access.
Empowering ideas, inspiring innovation, and creating future-ready solutions that move your vision forward—one bold step at a time.
